Fig. 6From: Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapyRibavirin dose reduction relative to ITPA polymorphism in HCV patients taking Sofosbuvir ribavirin therapy. The bars present number of patients experience ribavirin dose reduction by ITPA polymorphism rs1127354 CC and CA genotype and ITPA rs7270101 AA and Ac genotypeBack to article page